why Quest Diagnostics Incorporated [DGX] is a Good Choice for Investors After New Price Target of $140.00

Quest Diagnostics Incorporated [NYSE: DGX] jumped around 2.06 points on Friday, while shares priced at $120.20 at the close of the session, up 1.74%. The company report on October 15, 2020 that Fentanyl and Heroin Misuse Skyrockets During COVID-19 Pandemic, Finds Quest Diagnostics Health Trends Study.

Largest nationally representative study based on laboratory data shows double-digit increases in mixing of fentanyl with amphetamines and cocaine.

Convergence of drug misuse epidemic and COVID-19 pandemic creates perfect storm of drug use disorders, illuminating need for increased public health resources.

Quest Diagnostics Incorporated stock is now 12.56% up from its year-to-date (YTD) trading value. DGX Stock saw the intraday high of $122.86 and lowest of $118.55 per share. The company’s 52-week high price is 131.81, which means current price is +64.61% above from all time high which was touched on 07/23/20.

Compared to the average trading volume of 1.27M shares, DGX reached a trading volume of 1807196 in the most recent trading day, which is why market watchdogs consider the stock to be active.

What do top market gurus say about Quest Diagnostics Incorporated [DGX]?

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for DGX shares is $140.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on DGX stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

KeyBanc Capital Markets have made an estimate for Quest Diagnostics Incorporated shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on July 29, 2020. The new note on the price target was released on July 14, 2020, representing the official price target for Quest Diagnostics Incorporated stock. Previously, the target price had yet another raise from $90 to $120, while Wells Fargo kept a Equal Weight rating on DGX stock.

The Average True Range (ATR) for Quest Diagnostics Incorporated is set at 2.92, with the Price to Sales ratio for DGX stock in the period of the last 12 months amounting to 2.11. The Price to Book ratio for the last quarter was 2.76, with the Price to Cash per share for the same quarter was set at 7.48. Price to Free Cash Flow for DGX in the course of the last twelve months was 30.11 with Quick ratio for the last quarter at 1.20.

How has DGX stock performed recently?

Quest Diagnostics Incorporated [DGX] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 3.03. With this latest performance, DGX shares gained by 6.76% in over the last four-week period, additionally plugging by 26.49% over the last 6 months – not to mention a rise of 14.77% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for DGX stock in for the last two-week period is set at 64.26, with the RSI for the last a single of trading hit 74.48, and the three-weeks RSI is set at 59.54 for Quest Diagnostics Incorporated [DGX]. The present Moving Average for the last 50 days of trading for this stock 115.09, while it was recorded at 117.95 for the last single week of trading, and 109.77 for the last 200 days.

Quest Diagnostics Incorporated [DGX]: Deeper insight into the fundamentals

Operating Margin for any stock indicates how profitable investing would be, and Quest Diagnostics Incorporated [DGX] shares currently have an operating margin of +15.79 and a Gross Margin at +34.02. Quest Diagnostics Incorporated’s Net Margin is presently recorded at +10.81.

Return on Total Capital for DGX is now 11.89, given the latest momentum, and Return on Invested Capital for the company is 8.95. Return on Equity for this stock inclined to 15.38, with Return on Assets sitting at 7.00. When it comes to the capital structure of this company, Quest Diagnostics Incorporated [DGX] has a Total Debt to Total Equity ratio set at 96.01. Additionally, DGX Total Debt to Total Capital is recorded at 48.98, with Total Debt to Total Assets ending up at 42.17. Long-Term Debt to Equity for the company is recorded at 77.63, with the Long-Term Debt to Total Capital now at 39.60.

Reflecting on the efficiency of the workforce at the company, Quest Diagnostics Incorporated [DGX] managed to generate an average of $17,766 per employee. Receivables Turnover for the company is 7.44 with a Total Asset Turnover recorded at a value of 0.65.Quest Diagnostics Incorporated’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.20 and a Current Ratio set at 1.30.

Earnings analysis for Quest Diagnostics Incorporated [DGX]

With the latest financial reports released by the company, Quest Diagnostics Incorporated posted 1.76/share EPS, while the average EPS was predicted by analysts to be reported at 1.71/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 2.90%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for DGX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Quest Diagnostics Incorporated go to 11.70%.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam